Potential Impact of Rapid Multiplex PCR on Antimicrobial Therapy Guidance for Ventilated Hospital-Acquired Pneumonia in Critically Ill Patients, A Prospective Observational Clinical and Economic Study
Open Access
- 13 April 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Cellular and Infection Microbiology
- Vol. 12, 804611
Abstract
Objectives: To investigate the potential impact of the syndromic multiplex FilmArray® Pneumonia plus Panel (FAPP) on the antimicrobial treatment guidance of patients with ventilated hospital-acquired pneumonia (VHAP).Methods: Respiratory fluids from 100 adult patients with VHAP, receiving invasive mechanical ventilation in three intensive care units from one French university hospital, were tested prospectively using FAPP. Conventional cultures were performed in parallel as routine practice. Clinicians were left blinded to the FAPP results. Antimicrobial therapies based on FAPP results were simulated by independent blinded experts according to a predefined algorithm and compared to 1) those prescribed in practice according to local guidelines (real-life), and 2) those that complied with the international ERS/ESICM/ESCMID/ALAT recommendations. The primary endpoint was the number of days of broad-spectrum antimicrobial therapy. Secondary endpoints were the rates of microbiological treatment failure and cost-effectiveness ratio.Results: The predicted median duration of broad-spectrum antibiotics was 0 [0-1.25] day in the FAPP-based simulation, versus 2 [0-6] days in real-life (p<0.0001) and 2 [2-3.25] days in the recommendations-based simulation (p<0.0001). Treatment failure was predicted in 3% of cases with FAPP results versus observed in 11% in real-life (p=0.08) and 6% with recommendations-based simulation (p=0.37). The incremental cost-effectiveness ratio was 1 121 € [-7021; 6794] to avoid one day of non-optimized antimicrobial therapy.Conclusions: Our results suggest that using FAPP in patients with VHAP has the potential to reduce the use of broad-spectrum antimicrobial therapy without increasing the risk of microbial treatment failure.Keywords
This publication has 21 references indexed in Scilit:
- Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic SocietyClinical Infectious Diseases, 2016
- Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injuryEuropean Respiratory Journal, 2016
- Assessment of empirical antibiotic therapy optimisation in six hospitals: an observational cohort studyThe Lancet Infectious Diseases, 2014
- Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studiesThe Lancet Infectious Diseases, 2013
- Impact of Rapid Organism Identification via Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Combined With Antimicrobial Stewardship Team Intervention in Adult Patients With Bacteremia and CandidemiaClinical Infectious Diseases, 2013
- Emergence of Imipenem-Resistant Gram-Negative Bacilli in Intestinal Flora of Intensive Care PatientsAntimicrobial Agents and Chemotherapy, 2013
- Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factorsIntensive Care Medicine, 2013
- A flexible fixed-sequence testing method for hierarchically ordered correlated multiple endpoints in clinical trialsJournal of Statistical Planning and Inference, 2008
- Points to Consider on Multiplicity Issues in Clinical TrialsJapanese Journal of Biometrics, 2006
- Clinical and economic consequences of ventilator-associated pneumonia: A systematic reviewCritical Care Medicine, 2005